PALATIN TECHNOLOGIES INC
10-Q, EX-27, 2000-11-14
IN VITRO & IN VIVO DIAGNOSTIC SUBSTANCES
Previous: PALATIN TECHNOLOGIES INC, 10-Q, EX-10.3, 2000-11-14
Next: GLYNN CAPITAL MANAGEMENT /CA/, 13F-HR, 2000-11-14



<TABLE> <S> <C>

<ARTICLE>                     5
<LEGEND>
This schedule contains summary financial information extracted from the
registrant's unaudited consolidated financial statements for the three month
period ended September 30, 2000 and is qualified in its entirety by reference to
those financial statements.
</LEGEND>

<CURRENCY>                      U.S. Dollars

<S>                             <C>
<PERIOD-TYPE>                   3-MOS
<FISCAL-YEAR-END>                              JUN-30-2000
<PERIOD-START>                                  JUL-1-2000
<PERIOD-END>                                   SEP-30-2000
<EXCHANGE-RATE>                                          1
<CASH>                                          11,031,228
<SECURITIES>                                     3,218,836
<RECEIVABLES>                                      795,081
<ALLOWANCES>                                             0
<INVENTORY>                                              0
<CURRENT-ASSETS>                                14,788,366
<PP&E>                                           2,503,854
<DEPRECIATION>                                     981,464
<TOTAL-ASSETS>                                  17,013,840
<CURRENT-LIABILITIES>                            1,782,949
<BONDS>                                                  0
                                    0
                                          7,309
<COMMON>                                           100,230
<OTHER-SE>                                      15,123,352
<TOTAL-LIABILITY-AND-EQUITY>                    17,013,840
<SALES>                                                  0
<TOTAL-REVENUES>                                   855,081
<CGS>                                                    0
<TOTAL-COSTS>                                    3,162,172
<OTHER-EXPENSES>                                         0
<LOSS-PROVISION>                                         0
<INTEREST-EXPENSE>                                   2,280
<INCOME-PRETAX>                                 (2,222,079)
<INCOME-TAX>                                             0
<INCOME-CONTINUING>                             (2,222,079)
<DISCONTINUED>                                           0
<EXTRAORDINARY>                                          0
<CHANGES>                                                0
<NET-INCOME>                                    (2,222,079)
<EPS-BASIC>                                           (.27)
<EPS-DILUTED>                                         (.27)



</TABLE>


© 2022 IncJournal is not affiliated with or endorsed by the U.S. Securities and Exchange Commission